In contrast, in ER/PR-positive (HER2-negative) cancer samples, the immune-suppressive iTreg profile (high NFκB, JAK-STAT3, TGFβ, and Notch pathway activity scores) was most prominently present, compared to in the triple-negative cancer samples. Here, ERBB2 is linked to cancer.